© Copyright 2016 IP Research Consulting. All right reserved.
Navigation Menu

Welcome

Photeomix® pioneering technologies

that optimise the value of

proteomics

Photeomix an innovative biotechnology company is constantly refining and expanding its range of proprietary technologies for the detection of differentially active components of the proteome. Since 2005, IP Research Consulting SAS, commercial name Photeomix®, has been involved in the development of a new generation of disruptive assays for diagnostic testing and drug screening, based on the proprietary Activomics® platform. Entirely privately owned, the management strategy has steered ground- breaking research towards the development of new products via the formation of key partnerships with clinicians, academia and industry in order to move these innovations forwards to commercialisation. In 2016 thanks to a Phase I SME instrument from the EU’s Horizon 2020 programme, Photeomix® is aiming to consolidate its biomarker and diagnostic kit strategy whilst retaining its capacity for innovative research and development.

Activomics® our modular

platform may be applied to:

The assay of key regulatory enzymes The discovery of new enzymatic activities The identification of novel drug targets The discovery of biomarkers
More Info
© Copyright 2016 IP Research Consulting. All right reserved.
Home About Science & Technology Activomics Get involved Activomics-store Partners News Contact

Welcome

Photeomix® pioneering technologies that

optimise the value of proteomics

Photeomix an innovative biotechnology company is constantly refining and expanding its range of proprietary technologies for the detection of differentially active components of the proteome. Since 2005, IP Research Consulting SAS, commercial name Photeomix®, has been involved in the development of a new generation of disruptive assays for diagnostic testing and drug screening, based on the proprietary Activomics® platform. Entirely privately owned, the management strategy has steered ground-breaking research towards the development of new products via the formation of key partnerships with clinicians, academia and industry in order to move these innovations forwards to commercialisation. In 2016 thanks to a Phase I SME instrument from the EU’s Horizon 2020 programme, Photeomix®  is aiming to consolidate its biomarker and diagnostic kit strategy whilst retaining its capacity for innovative research and development.

Activomics® our

modular platform may

be applied to:

The assay of key regulatory enzymes The discovery of new enzymatic activities The identification of novel drug targets The discovery of biomarkers
More Info Home